CTCX

Carmell Corporation Class A · NASDAQ

Sector Consumer Non-Durables
Industry Household/Personal Care
Website carmellrx.com
Employees(FY) 14
ISIN US1429221039

Performance

+40.53%

+6.15%

-45.92%

-86.14%

-90.94%

YTD

-88.76%

Profile

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of CTCX 2024-12-02

The stock indicators reflect a neutral sentiment overall, with the Moving Average Score at 56, Oscillators Score at 60, and Technical Score at 58, suggesting a balanced market condition. While the Oscillators indicate a slightly bullish momentum, the other scores reinforce a cautious outlook, highlighting the need for further confirmation before...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CTCX

Stock Rank

Recent News & Updates

2024-09-04 20:30
Carmell Corporation Launches Skincare Partnership With Ladies Playbook to Support and Celebrate NFL Sports Community(Globenewswire)
2024-07-28 20:30
Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index(Globenewswire)
2024-05-15 20:54
CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023(Investorplace)
2024-04-11 04:30
Carmell Announces Successful Closing of $3.0 Million Private Placement(Globenewswire)
2024-04-03 20:30
Carmell Announces $3.0 Million Private Placement(Globenewswire)
2024-03-26 21:15
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction(Globenewswire)
2024-03-20 04:39
Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary(Globenewswire)
2024-03-18 03:16
Carmell to Host Investor Webinar, Unveiling the Secretome: On the Eve of Product Launch Featuring Key Opinion Leaders in the Medical Aesthetics Field(Globenewswire)
2024-02-25 19:30
Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024(Globenewswire)
2023-11-15 19:30
Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors(Globenewswire)
2023-09-12 00:35
Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine(Yahoo Finance)
2023-09-05 06:03
Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics(Yahoo Finance)
2023-08-09 03:41
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity(Yahoo Finance)
2023-07-26 19:00
Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company(Yahoo Finance)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.